Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,052,987

« Back to Dashboard

Which drugs does patent 8,052,987 protect, and when does it expire?

Patent 8,052,987 protects RECLAST and is included in one NDA. There has been one Paragraph IV challenge on Reclast.

This patent has thirty-eight patent family members in twenty-eight countries.

Summary for Patent: 8,052,987

Title:Method of administering bisphosphonates
Abstract: The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
Inventor(s): Horowitz; Zebulun D. (Basking Ridge, NJ), Richardson; Peter C. (Far Hills, NJ), Trechsel; Ulrich (Luzein, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:10/311,942
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
zoledronic acid
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,052,987

PCT Information
PCT FiledJune 18, 2001PCT Application Number:PCT/EP01/06850
PCT Publication Date:December 27, 2001PCT Publication Number: WO01/97788

International Patent Family for Patent: 8,052,987

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria304856► Subscribe
Australia2001274109► Subscribe
Australia7410901► Subscribe
Brazil0111806► Subscribe
Canada2410201► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus